Wells Fargo’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $560K | Sell |
14,291
-28,765
| -67% | -$797K | ﹤0.01% | 4095 |
|
|
2025
Q4 | $663K | Buy |
43,056
+17,232
| +67% | +$343K | ﹤0.01% | 4267 |
|
|
2025
Q3 | $529K | Buy |
25,824
+9,168
| +55% | +$185K | ﹤0.01% | 4268 |
|
|
2025
Q2 | $334K | Sell |
16,656
-1,057
| -6% | -$20K | ﹤0.01% | 4429 |
|
|
2025
Q1 | $349K | Buy |
17,713
+1,047
| +6% | +$22.5K | ﹤0.01% | 4332 |
|
|
2024
Q4 | $375K | Buy |
16,666
+5,548
| +50% | +$144K | ﹤0.01% | 4378 |
|
|
2024
Q3 | $284K | Sell |
11,118
-371
| -3% | -$8.59K | ﹤0.01% | 4349 |
|
|
2024
Q2 | $268K | Buy |
11,489
+3,274
| +40% | +$68.9K | ﹤0.01% | 4315 |
|
|
2024
Q1 | $145K | Buy |
8,215
+1,057
| +15% | +$16.2K | ﹤0.01% | 4671 |
|
|
2023
Q4 | $99.1K | Buy |
7,158
+1,418
| +25% | +$17.3K | ﹤0.01% | 4906 |
|
|
2023
Q3 | $78.4K | Sell |
5,740
-3,130
| -35% | -$52.7K | ﹤0.01% | 4924 |
|
|
2023
Q2 | $181K | Buy |
8,870
+8,846
| +36,858% | +$179K | ﹤0.01% | 4638 |
|
|
2023
Q1 | $526 | Hold |
24
| – | – | ﹤0.01% | 6546 |
|
|
2022
Q4 | $397 | Hold |
24
| – | – | ﹤0.01% | 6443 |
|
|
2022
Q3 | $0 | Buy |
24
+3
| +14% | +$18 | ﹤0.01% | 6814 |
|
|
2022
Q2 | $0 | Buy |
21
+1
| +5% | +$5 | ﹤0.01% | 6962 |
|
|
2022
Q1 | $0 | Hold |
20
| – | – | ﹤0.01% | 7227 |
|
|
2021
Q4 | $0 | Hold |
20
| – | – | ﹤0.01% | 7346 |
|
|
2021
Q3 | $0 | Buy |
20
+12
| +150% | +$249 | ﹤0.01% | 7074 |
|
|
2021
Q2 | $0 | Sell |
8
-576
| -99% | -$17.9K | ﹤0.01% | 7004 |
|
|
2021
Q1 | $20K | Sell |
584
-383
| -40% | -$19.5K | ﹤0.01% | 6150 |
|
|
2020
Q4 | $85K | Buy |
967
+562
| +139% | +$47.2K | ﹤0.01% | 5418 |
|
|
2020
Q3 | $33K | Sell |
405
-285
| -41% | -$25.7K | ﹤0.01% | 5635 |
|
|
2020
Q2 | $76K | Buy |
+690
| New | +$77.2K | ﹤0.01% | 5348 |
|
Other funds holding ELVN
O
PCH
CC
VPC
BG
VCM
FFM
